Biotechnology

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

As Chair Ilona Haaijer announces her 2026 departure, Corbion's seamless succession plan reveals a masterclass in governance and strategic continuity.

Senté renewed its pact with a top scientist. We explore how deep scientific partnerships are becoming the key differentiator in a crowded, hype-filled market.

Beyond the headlines of a new cancer therapy, French biotech Oncovita is executing a masterclass in strategy, leveraging a modified measles virus and AI.

A new alliance between Made Scientific and Pluristyx promises to slash the time and cost of developing advanced iPSC therapies. But can it deliver on its promise?

The 3rd annual National STEM Festival brings PhD-level student research to D.C., connecting young builders with leaders to solve real-world workforce shortages.

Australian biotech Gelteq is opening a China R&D hub to chase explosive growth, but its bold move into a $60B market comes with significant geopolitical risks.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Eli Lilly's partnership with cash-pay platform Sesame is more than a deal; it's a blueprint for a decentralized, direct-to-consumer healthcare market.

Scilex sets a date to pay out Semnur stock to its shareholders. We dig into whether this is a true value unlock or a move born from financial pressure.

As NEXGEL prepares for a key investor conference, it faces a crucial test: convincing the market its advanced hydrogel tech can overcome recent financial hurdles.

As the deadly Bundibugyo Ebola strain spreads with no approved vaccine, a small pharma company is positioning its cancer drug as a potential broad-spectrum shield.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

Teva's new Eylea biosimilar hits Europe, a key move in its 'Pivot to Growth' strategy that promises to shake up the lucrative ophthalmology market.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

A first-in-class drug aims to calm overactive immune cells, offering a new blueprint for treating diseases like rheumatoid arthritis. But can it deliver?

The successful Hong Kong IPO of a LanzaTech joint venture isn't just a financial win; it's a market validation for turning pollution into valuable products.

With its first product launch, Daré Bioscience enters a new commercial era. But can a single probiotic launch secure the future of its ambitious pipeline?